TIDMSLN

RNS Number : 5538T

Silence Therapeutics PLC

26 March 2021

Block Listing Application

March 26, 2021

LONDON, Silence Therapeutics plc, AIM:SLN and Nasdaq: SLN ("Silence" or "the Company") a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, has today made an application to the London Stock Exchange for a block listing of 3,300,000 ordinary shares of 5 pence each in the Company ("Block Listing Shares") to be admitted to trading on the London Stock Exchange ("Admission").

Admission is expected to become effective on 31 March 2021.

These shares are being reserved under a block listing and will be allotted from time to time pursuant to the Silence Therapeutics plc 2018 Employee Long Term Incentive Plan and will rank pari passu with the existing Ordinary Shares of the Company.

Enquiries:

 
 Silence Therapeutics plc                                Tel: +1 (646) 637-3208 
  Gem Hopkins, Head of IR and Corporate Communications 
  ir@silence-therapeutics.com 
   Investec Bank plc (Nominated Adviser and               Tel: +44 (0) 20 
    Broker)                                                7597 5970 
    Daniel Adams/Gary Clarence 
 European PR                                             Tel: +44 (0) 20 
  Consilium Strategic Communications                      3709 5700 
  Mary-Jane Elliott/ Angela Gray / Chris Welsh 
  silencetherapeutics@consilium-comms.com 
 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet medical need. Silence's proprietary messenger RNAi GOLD(TM) platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron loading anemias. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Takeda, among others. For more information, please visit https://www.silence-therapeutics.com/.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ALSQELFLFXLEBBK

(END) Dow Jones Newswires

March 26, 2021 03:00 ET (07:00 GMT)